Further to the question of high unmet need there are as I said numerous references but a quick look back at the VLA Newsletter of June 2017 Dr. Malcolm McColl amongst other things said,
"We can now see a potential path to the US market in the significant number of melanoma patients who have progressed following treatment with checkpoint therapies such as YERVOY and KEYTRUDA®3. There is a high unmet need in this setting, and with ongoing positive results, we are developing plans for a Phase 3 pivotal registration study."
VLA Price at posting:
74.0¢ Sentiment: Hold Disclosure: Held
